Business
SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference
DENVER, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Ra
About this update from Seastar Medical Holding Corporation
[{"type":"image","alt":"SeaStar Medical","displaySize":"","headline":null,"caption":"SeaStar Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/4c7240b3e0b5bc01bb2108fbeef0b4c6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LUjJFfXNTg2cjq9rPHCJQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4c7240b3e0b5bc01bb2108fbeef0b4c6","width":300,"height":110}},"lazy":false},{"type":"text","content":"DENVER, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, Florida on Wednesday, December 3rd at 4:00 pm Eastern Standard Time.","length":573,"tagName":"p"},{"type":"text","content":"Interested investors and guests of SeaStar Medical are welcome to attend the conference. Please register here using the code ICUNOBLECON for the SeaStar Medical participation rate.","length":180,"tagName":"p"},{"type":"text","content":"A replay of the presentation will be available on Thursday, December 4th after 4:00 pm Eastern Standard Time on the Company's website and can be accessed here. The replay will be available for up to 30 days following its posting.","length":233,"tagName":"p"},{"type":"text","content":"About SeaStar Medical","length":21,"tagName":"p"},{"type":"text","content":"SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medic...